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Acute respiratory distress syndrome (ARDS) is a pulmonary disease that causes
hypoxemia and respiratory failure. The mortality rate for ARDS ranges between 27% and
45%. Current treatments including mechanical ventilation and extracorporeal membrane
oxygenation (ECMO) are often associated with high risk complications including
barotrauma, infection, thrombosis, and hemorrhage. Alternative pulmonary support
techniques are needed to improve the survival rate of patients suffering from ARDS.
Previous studies introducing pure O2 gas, perfluorocarbons and red blood cells into the
intraperitoneal (IP) cavity have reported no effect or only a mild increase in oxygenation.
Here we report peritoneal membrane oxygenation (PMO) using phospholipid-coated
oxygen microbubbles (OMBs). OMBs are oxygen carriers that have unique physical and
chemical properties. We hypothesize that IP infusion of OMBs can provide
supplementary oxygenation for rats with ARDS and hypoxemia, thus allowing time for
essential recovery of the lungs.
We designed a bolus delivery device that automatically and periodically infuses
OMBs to the rat’s IP cavity. In addition, the device flushes the cavity with saline,
scavenges the perfusate, maintains safe intra-abdominal pressure, and regulates perfusate
temperatures to body temperature.
In order to understand the mechanism by which intraperitoneal OMB infusion
improves systemic oxygenation, we examined, both in theory and in vivo, the kinetics of

oxygen transport from OMBs to blood capillaries of healthy rats. A 1D mathematical
model was developed using Fick’s laws to predict the oxygen diffusion rate across the
peritoneum. In vivo measurements of the gas content of OMBs after 20 minutes of dwell
time in the IP cavity of rats were further used to determine the oxygen diffusion rate,
which was found to be within the predicted range. Also, we are able to demonstrate in
vivo that OMBs not only can provide O2 to the body, but also can absorb CO2 and
possibly other gases, such as N2, from the body. PMO represents an alternative
extrapulmonary technique of oxygenation and ventilation that is a potential treatment for
acute respiratory failure in the future.
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Chapter 1: Introduction
Acute respiratory failure is a life threatening condition in which the respiratory
system fails in one or both of its gas exchange functions, which include oxygenation and
CO2 elimination [1] [2]. Treatment of patients with severe respiratory failure requiring
mechanical support is done in an intensive care unit. Acute respiratory distress syndrome
(ARDS) is the most severe form of acute lung injury. It is a rapidly progressive disease
that leads to low oxygen levels in blood known as hypoxemia. According to a study in
2005, about 190,000 people in the U.S. develop ARDS annually [3]. Many people who
develop ARDS do not survive due to its high mortality, which can be as high as 45% [4].
The risk of death increases with age and severity of illness. Of the people who do survive
ARDS, some recover to near-normal function while others experience lasting damage to
their lungs. In this study we explore a possible way of oxygenation hoping that this
technique may be useful to decrease the morbidity and mortality of patients suffering
from ARDS in the near future.

1.1 Scope and Organization of Thesis
Chapter one focuses on the background knowledge on ARDS required to
understand the motivation behind this study. Chapter two describes the experimental
design and results for finding a reliable way to remove oxygen microbubbles (OMBs)
from the intraperitoneal (IP) cavity after injection. Chapter three describes the design and
development of an automatic oxygen microbubble (OMB) delivery device, which can be
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used for testing the effectiveness of peritoneal membrane oxygenation (PMO) as a
treatment for ARDS rats. Chapter four includes the modeling work done to predict the
kinetics of oxygen diffusion from OMBs to venous blood in peritoneum tissue. Chapter
five describes in vivo experiments for gas analysis of OMBs after injection to the IP
cavity of rats. Chapter five is a discussion of the findings and conclusions.

1.2 Acute Respiratory Distress Syndrome
1.2.1 Pathophysiology of ARDS
The human lungs are a pair of spongy, air-filled respiratory organs located on either
side of the thoracic cavity in the chest. At the microscopic level are small air sacs called
alveoli (Figure 1.1 a). Between the walls of the alveoli is a thin layer of cells called the
interstitium, which contains cells, fibers, and blood vessels that help support the alveoli.
The thickness of the alveolar-capillary barrier is 0.65 µm [5]. The total surface area of the
alveoli is approximately 75 m2 in humans, which is similar to the surface area of a tennis
court [6]. Oxygen diffuses from the air in the alveoli to the blood in the small capillaries
surrounding the alveoli, while CO2, a waste product of metabolism, diffuses from the
blood to the alveoli, where it can be exhaled.
At the microstructure level, ARDS affects the alveoli in the lungs. Direct or
indirect lung injury initiates an inflammatory-immune response that activates neutrophils,
macrophages, and platelets to the injured sites [7]. Circulating neutrophils adhere to the
endothelium of pulmonary capillaries and release chemical mediators resulting in damage
to the alveolo-capillary membrane allowing fluid release from the capillary filling the
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alveolar space [8]. When protein rich edema fluid accumulates in the alveolar space, this
obstructs the lungs from oxygenating the blood thus leading to hypoxemia (Figure 1.1b).
In addition, neutrophils pass through the leaky capillaries and produce an inflammatory
response in the lung epithelium, resulting in further damage to the lungs and respiratory
decompensation [9]. The release of inflammatory mediators from damaged lung tissue
triggers a systemic inflammatory immune response causing multi-organ failure, which is
the main cause of death in ARDS patients [10].

Figure 1.1 Lung alveoli (a) normal and (b) ARDS
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Radiographically, a chest X-ray shows bilateral diffuse infiltrates occupying most
of the lung fields indicating ARDS (Figure 1.2b). A normal chest X-ray shows clear lung
fields (Figure 1.2a).

Figure 1.2 Chest X-ray (a) normal patient showing clear lung fields and (b) patient with
ARDS showing bilateral diffuse infiltrates [11] [12]

There are several causes of ARDS. Infectious etiologies such as sepsis,
bacteremia and severe pneumonia are the most prominent. Systemic inflammatory
conditions such as severe pancreatitis can also lead to ARDS. Inhalation of toxic
chemicals or smoke can cause ARDS by direct injury to the alveoli and capillaries. In
addition, traumatic injuries to the head or chest could contribute to the etiology of ARDS.
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1.2.2 Available Treatment for ARDS
The first goal in treating ARDS is to improve the levels of oxygen in the blood to
prevent organ failure. For mild disease, oxygen may be delivered through a mask that fits
tightly over the nose and mouth to provide supplemental oxygenation. Most people with
moderate or severe ARDS will need to be intubated and placed on a mechanical
ventilator (MV) to either support or completely control the breathing of the patient
(Figure 1.3a) [13]. MV pushes air into the lungs and forces some of the fluid out of the
air sacs. It is currently the best treatment option available. However, MV does have side
effects. Some patients experience alveolar hyperdistention and cyclic closing and
reopening of the alveoli during positive pressure ventilation that leads to volutrauma
(increased lung volume) and barotrauma (increased lung pressure). These traumatic
changes in lung volume and pressure can lead to ventilator associated lung injury
(VALI). VALI can then trigger a pulmonary and systemic inflammatory reaction that
may lead multiple organ dysfunction and multiple system organ failure [10]. Although
the mortality rate of respiratory illnesses decreased over recent years due to the advances
in MV, it still remains high [14].
To support patients with severe ARDS who have failed MV or other conventional
ventilator rescue techniques, researchers looked into the idea of extrapulmonary
ventilation to bypass the damaged lungs and supply oxygen directly to the blood while
allowing the lung injury to heal. Extracorporeal membrane oxygenation (ECMO) is an
extracorporeal technique of providing respiratory support to patients whose lungs are
unable to provide an adequate amount of gas exchange to sustain life [15]. This method
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pumps blood out from the body into a diffusion membrane, artificially adding oxygen
into the red blood cells (RBCs) and removing CO2, and then pumps blood back to the
patient (Figure 1.3b). ECMO was first introduced in the 1970’s [16]. Historically, ECMO
use has centered on neonatal care [17]. A recent increase in adult ECMO use can be
attributed to H1N1-induced ARDS across the globe. It is commonly used as a last resort
treatment in patients suffering from very severe ARDS. The survival rate of ECMO is
47.7% [18]. ECMO is an invasive technique that has a high cost and complexity, which
restrict its use in ambulatory situations. In addition, it is associated with high risk
complications such as infection, thrombosis and hemorrhaging [19]. ECMO can support
gas exchange in patients failing conventional mechanical ventilation, but proper patient
selection and ultimate poor outcomes makes its use controversial. Therefore, alternative
pulmonary support techniques are needed to improve the survival of patients with ARDS.

Figure 1.3 Available treatment for ARDS patients. (a) Mechanical ventilation and (b)
ECMO
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1.2.3 Classification and Prognosis of ARDS
In 2011 a panel of experts established the Berlin criteria to classify ARDS (Table
1.1). ARDS was best classified as mild, moderate and severe based on the ratio of partial
pressure of arterial oxygen and fraction of inspired oxygen (PaO2/FiO2) [20]. This
classification was also based on prognostic measures. As shown in the table below, the
mortality rate and duration of mechanical ventilation is proportional to the severity of
ARDS and PaO2/FiO2 ratio. Patients with severe disease having the highest oxygen need
have a high mortality up to 45% and spend on average 9 days on the ventilator, while
patients with mild disease have a lower mortality of 27% and spend an average of 5 days
on the ventilator.

Table 1.1 Berlin criteria for defining ARDS [20]
ARDS

PaO2/FiO2

Mortality (95% CI)

Duration on Mechanical
Ventilation (days)

Mild

≤ 300

27% (24-30)

5

Moderate

≤ 200

32% (29-34)

7

Severe

≤ 100

45% (42-48)

9

1.3 Peritoneal Membrane Oxygenation
Alternative extrapulmonary respiration methods have been explored, such as
peritoneal membrane oxygenation (PMO). This idea was first proposed in 1934 to
mechanically ventilate the peritoneal cavity with oxygen [21]. This idea translates from
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the concept of peritoneal dialysis. Peritoneal dialysis is a well-known technique that has
been widely accepted for the treatment of end stage renal failure since 1923 [22]. This
technique exchanges solute and fluid across the peritoneum and is simple and less
expensive than hemodialysis (Figure 1.4) [23]. The most common complications from
peritoneal dialysis include infection around the catheter site or infection of the lining of
the abdominal wall also known as peritonitis.

Figure 1.4 Peritoneal dialysis [24]

The peritoneum is a thin, continuous, translucent membrane, which covers the
visceral organs and the abdominal wall. It is composed of a mesothelial single cell layer,
interstitial tissue and blood capillaries. The average surface area of the peritoneum
membrane (PM) is 1.3 m2 in adults [25]. PMO follows the same concept as dialysis, but
uses the peritoneum for gas exchange. This method shows promise as it is a simple
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procedure with easy access of the peritoneal cavity for catheterization, and relative safety
with low risk complications compared to an extracorporeal circuit [26] [27].
One study observed the effects of transperitoneal ventilation with pure O2 gas on
death time in asphyxiated rabbits [28]. All animals died successively after asphyxia. In
addition, there was no significant increase in PaO2. This study failed because the surface
area was minimized owing to the high surface free energy (~73 mJ/m2) of the gas/water
interface. Another study aimed to determine whether systemic oxygenation could be
increased in pigs, with induced hypoxia, by perfusing the abdominal cavity with
oxygenated perfluorocarbons (PFCs) [29]. The most clinically relevant results occurred at
an FiO2 of 14%, resulting in a baseline mean PaO2 of 39.4 ± 5.0 mm Hg with oxygenated
saline solution perfusion, and a mean PaO2 of 55.3 ± 7.6 mm Hg with oxygenated PFC
perfusion. Infusion of RBCs into the intraperitoneal (IP) cavity of dogs resulted only a
mild increase in oxygen partial pressures [30]. These prior attempts have not been able to
show clinically relevant results. This may be due to the low biocompatibility and low
oxygen transfer efficiencies of the oxygen carrier utilized, which might explain their
failure to oxygenate the body. The most successful application of peritoneal oxygenation
used liposomal synthetic hemoglobin, which produced a mean increase in rat cardiac
arrest time following a right pneumothorax from 9 to 33 min [31].
Our proposed solution is to us oxygen microbubbles (OMBs), an innovative
oxygen carrier with unique physical and chemical properties. The original clinical
utilities of gas-filled particles are as ultrasound contrast agents filled with an inert
insoluble gas and drug delivery vehicles [32]. Such suspensions are not well suited for
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gas delivery because they are typically designed to have low gas fractions and prolonged
circulation. However, OMBs (70% vol) are designed to be smaller than 15 μm in
diameter suspended in saline (30% vol). They contain pure O2 gas core encapsulated by a
phospholipid monolayer composed of 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC) and polyethylene glycol (PEG) brush combined in a 9:1 molar ratio (Figure 1.5).
PEG forms coils (~10 nm in height) that provide steric repulsion to prevent microbubble
coalescence. The phospholipid monolayer membrane is 3 nm thick, which reduces
surface tension and provides rigidity. The bubble’s shell comprises only ~1% of the total
microbubble volume. OMBs mimic the structure and composition of natural lung alveoli.
The bubble shell is highly permeable to O2 and other gases, allowing continuous diffusive
exchange with surrounding dissolved gases [33].

Figure 1.5 (a) OMB vial and (b) microstructure of OMBs [34]
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A 70% volume suspension of OMBs at atmospheric pressure and 37 °C contains
an estimated 0.88 mg-O2/mL [34]. Table 1.2 compares the oxygen carrying capacity of
RBCs, PFCs, liposomal hemoglobin (Hb), and pure oxygen gas. OMBs can carry oxygen
0.88 mg-O2/mL, which is higher than other aqueous carriers used at same temperature
and pressure. Although pure O2 gas has 1.26 mg-O2/mL, the oxygen carrying capacity is
not the only criterion for efficient oxygen transport. Oxygen diffusion also depends on
the surface area by Fick’s law relation. The overall rate of diffusion of gas is equal to the
product of the flux and area. Pure oxygen gas in the peritoneal cavity has a high surface
free energy (~73 mJ/m2) of the gas/water interface. Thus, the surface area for diffusion is
drastically minimized [34].

Table 1.2 Oxygen carrying capacity at body temperature and atmospheric pressure
O2 carrier

OMBs

RBCs

Liposomal Hb

PFC

O2 gas

Capacity
(mg-O2/mL)

0.88

0.31

0.62

0.57

1.26

A recent study by Kheir et al. [35] characterized the release kinetics of O2 gas
from OMBs to blood. When OMBs were mixed with human deoxygenated blood ex vivo,
O2 diffusion was complete within only 4 sec. They also investigated intravenous injection
of OMBs in rabbit hypoxic ventilation and tracheal clamp asphyxiation. OMBs supplied
the animals’ full oxygen consumption for 15 min, and decreased the incidence of cardiac
arrest and organ injury from asphyxia. The intravenous treatment with OMBs appears to
be a promising method for short-term rescue. However, prolonged continuous infusion of
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OMBs into the bloodstream has risks of embolism, thrombosis, and toxicities of lipid and
saline that remains in blood circulation. Therefore, a different approach is needed for
long term therapy of ARDS avoiding complications associated with injection of OMBs
into the bloodstream.
Previous work has shown that OMBs delivered intraperitoneally maintain
hemoglobin oxygen saturations at normal levels and provide 100% survival for rats with
a right-sided pneumothorax for at least 2 hours. In comparison, untreated rats and rats
treated with peritoneal oxygenated saline died within 30 min [34]. Another study showed
that PMO therapy can double the survival time of rabbits after complete tracheal
occlusion from 6.6 ± 0.6 min (average ± SD) for the saline controls to 12.2 ± 3.0 min for
the bolus OMB treated rabbits [36]. These results show that OMBs have potential to be
an alternative mechanism of oxygen delivery when injected intraperitoneally.
Previous work characterized the properties of OMBs ex vivo [37] [33], but there is
a need to conduct research to study the rate of oxygen delivery in vivo. Also further
studies are needed to test the potential of OMBs in absorbing CO2 in vivo. Our team
recently demonstrated that PMO can significantly increase survival in rats suffering a
right pneumothorax and rabbits suffering complete tracheal occlusion. In order to proceed
into a more clinically relevant disease model, the goal of the proposed study is to develop
and test PMO therapy in a clinically relevant rat model of mild to severe ARDS in rats.
We hypothesize that intraperitoneal infusion of OMBs can be used as a supplementary
method of oxygen delivery and CO2 removal for rats with ARDS thus allows time for
essential recovery of the lungs.
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1.4 Research Objectives
The overall goal of this research is to considerably increase the survivability of
patients with ARDS by providing alternative extrapulmonary oxygenation using OMBs.
In pursuit of this goal, the specific aims of this research is to first finalize the
development and validation of an OMB delivery system that will automatically infuse
and remove OMBs from the rat’s IP cavity. This device can be used for a long term study
for testing PMO as a potential treatment for ARDS in rats.
We aim to understand the mechanism by which intraperitoneal OMB infusion
improves systemic oxygenation, by examining the OMB gas exchange properties with the
PM by both theoretical modeling and in vivo tests. A one dimensional mathematical
model developed using Fick’s laws can predict the oxygen transport rate from OMBs to
peritoneum blood. A model would help us understand in theory the kinetics of oxygen
transport and how that would relate to the normal oxygen consumption need in rats. In
addition, it can predict whether continuous infusion or periodic bolus infusion of OMBs
is more efficient in oxygen delivery. One way for experimental validation of the model is
by measuring O2 delivery and CO2 removal by OMBs after infusion to the IP cavity of
rats. These measurements can be used to calculate the oxygen diffusion rate in vivo and
compared to our modeled oxygen kinetics. Finally, we aim to determine the optimal
perfusion dosage and dwell time of OMBs in the IP cavity of rats.
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Chapter 2: Aspiration of OMBs from the
Intraperitoneal Space
2.1 Introduction
Injection of OMBs into the IP cavity of rats can be applied by a needle or a
catheter implanted in the lower abdomen. The purpose of this experiment is to find a
reliable aspiration technique of OMBs after an IP injection. Aspiration is needed in
experiments involving studying the gas content of OMBs after dwelling in the IP space.
In addition, IP infusion of OMBs for several days to treat ARDS will lead to
accumulation of saline and lipids in the IP cavity. If intra-abdominal pressure exceeds
safe limits this could interfere with the hemodynamics of the abdomen and limit the
blood supply to abdominal organs. In order to prevent inducing abdominal compartment
syndrome, OMBs need to be removed from the IP space. Previous attempts by our group
to aspire the injected OMBs after dwelling in rat’s IP cavity were unsuccessful using
small needles. In this experiment, different needle diameters were tested, in addition to a
side opening teat tube (SOTT), and a peritoneal lavage catheter (PLC) (Figure 2.1a,b).

2.2 Materials and Methods
Male Wistar rats (n = 5, m = 539 g) were housed and acclimated for four days,
and cared for according to the University of Nebraska-Lincoln Institutional and Animal
Care and Use Committee (IACUC) guidelines. All rats were sedated using ketamine-
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xylazine (18-2 mg/kg) and placed in the supine position on a warming pad (T/pump
Classic, Gaymar) set at 38 °C to maintain body temperature. Paw pinches were made to
verify full sedation. The rat was then placed in a supine position on the surgery table.
Previous studies showed that an IP volume injection of 60 mL was considered to
be safe for ~ 500 g rats [38] [39]. OMBs were stored in a cooled environment at 5 °C
prior to the experiment to preserve their composition and structure. A 60 mL syringe was
used to extract OMBs from the vial, and the syringe was left at room temperature for 5
minutes. A 60 mL single bolus of OMBs was injected into the IP cavity within 1 minute.
After injection, OMBs were allowed to dwell for 2 minutes so that OMBs were naturally
distributed inside the cavity. After dwell, OMBs were manually aspirated by pulling out
the plunger of the syringe. The volume of OMBs aspirated was recorded, and the
aspirated OMBs were transferred into a waste beaker. The same volume of fresh OMBs
was injected in the IP cavity using the next larger needle and allowed to dwell for 2
minutes. This preserves a total of 60 mL OMBs in the IP cavity. Three different methods
were tested, which include needles of increasing size (18G, 16G, 14G, 11G, and 10G), an
SOTT, and a PLC (JP7, Mila International, Erlanger, KY) catheter were tested. Table 2.1
shows the inner diameter (ID) and length of the needles, SOTT, and PLC used. For the
11G, 10G, and SOTT, a scalpel was used to make a small incision in the lower right
quadrant of the abdominal cavity to accommodate for the larger diameters. All items
were placed in the same incision to minimize injury to the rat. For placing the catheter, a
small incision into the skin was made to expose the fascia of the abdominal wall. A PLC
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outflow catheter (PLC) was surgically implanted in the IP cavity and sutured to the skin.
Finally, the rat was sacrificed using CO2 inhalation.

2.3 Statistical Analysis
Multiple t-tests assuming equal variances was performed on the volumes of
aspirated OMBs to test for any differences between all groups. All tests used the same
level of significance (α = 0.05).

Figure 2.1 Items tested for aspirating OMBs (a) Side opening teat tube and (b) peritoneal
lavage catheter
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Table 2.1 Size of the needles and catheters tested for aspiration of OMBs
Needles

Cannula

Catheter

Size
18G

16G

14G

11G

10G

SOTT

PLC

ID (mm)

0.8

1.2

1.6

2.4

2.7

1.5

7

Length (cm)

2

3.8

2.5

2

2

6

20

2.4 Results and Analysis
The aspirated volumes of OMBs are shown in Appendix A. The means ± SD were
plotted on a bar graph in Figure 2.2. The PLC had the highest average of aspired volume
of 30 ± 6.3 mL. There is significant statistical difference between the means of PLC and
each of SOTT, 10G, 14G, and 18G needles ( ‘***’ p<0.001).
Volumes of approximately 0 mL OMBs aspirated were due to omental occlusion
(OO). Occlusion occurs when fatty abdominal tissue (omentum) occludes the tip of the
needle while applying a suction force using the syringe. Table 2.2 summarizes the
frequency of OO occurrence for each item. Occurrence of omental occlusion (per 5 rats)
was between 2 to 4 using needles (between 18G and 10G ) compared to none using the
lavage catheter. In other words, during aspiration needles had a high failure rate of 50 –
80%, while the PLC had 0% failure.
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Table 2.2 Frequency of omental occlusion occurred using each item (n=5)
Item

18G

16G

14G

11G

10G

SOTT

PLC

Frequency of OO

3

2

4

3

3

1

0

Figure 2.2 Aspiration volumes (mean ± SD) of OMBs using different items. Significant
difference is indicated by ‘***’ (p<0.001)

The needles had a wide range of aspiration volumes of spent OMBs ranging from
0 to 43 mL. The variation was mainly due to the high probability of omental plug during
aspiration. PLC successfully aspirated an average of half of the injected OMBs, with a
relatively low SD over the 5 trials. PLC has proven to be the most reliable and efficient
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method to extract the OMBs. Its advantages over needles and SOTT are its flexibility,
wider diameter, its numerous pores and increased length that allows a large surface area
in the IP cavity and subsequently allows better aspiration of OMBs. Thus, PLC can be
used for long term studies were it can be surgically implanted in the IP cavity unlike
needles or SOTT. In addition, the PLC can be used in experiments that require extraction
of OMBs from the IP space for gas content measurements.
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Chapter 3: OMB Infusion Device
3.1 Introduction
The mortality rate of patients with ARDS remains high even with the
advancements in mechanical ventilation and ECMO. Alternative extrapulmonary
ventilation techniques such as peritoneal membrane oxygenation are still being explored
as a potential therapy for ARDS. With the development of a promising oxygen carrier, a
device is needed to deliver OMBs intraperitoneally. The system will be used for studying
PMO with conscious and ambulatory rats of mild to severe ARDS. To evaluate
improvements of oxygen levels in blood and survivability, the length of the study will be
at least 3 days after inducing ARDS to rats and administering OMB treatment. Manual
infusion and removal of the perfusate to the cavity is a time consuming and exhaustive
procedure. In addition, continuous or periodic infusion of OMBs for several days results
in accumulation of lipids and saline (30% vol) in the IP space thus could limit the blood
supply to abdominal organs if IP pressure exceeds safe limits. Therefore, an automatic
system for infusion and scavenging of OMBs is needed for this study.
The design of the delivery device was established in a manner similar to
peritoneal dialysis catheter placement. A preliminary design was developed for
continuous infusion of OMBs, which consisted of two catheters implanted in the cavity,
one for inflow, and PLC for outflow. However, in vivo testing of the continuous infusion
system first prototype revealed advanced tissue obstruction and growth in the PLC after
four days. This was a major problem as it prevented further removal of fluid from the
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cavity. In addition, OMBs need to dwell in the cavity for gas exchange to occur (Chapters
4 and 5).Therefore, the design was revised to implement a periodic bolus system that is
simpler and effective. This chapter focuses on describing the current bolus delivery
system. The device will automatically infuse and scavenge OMBs, maintain safe intraabdominal pressure, and regulate perfusate temperatures to body temperature.

3.2 Materials and Methods
A schematic of the delivery system (Figure 3.1) includes OMB storage, periodic
infusion of OMBs, intra-abdominal pressure (IA) pressure measurement and control,
temperature measurement and control, tubing restraint, data acquisition and LabVIEW
control.

Figure 3.1 Schematic of the bolus delivery system for conscious rats
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3.2.1 OMB storage
OMBs require a cool, rotating, and pure humid O2 environment to avoid
breakdown of the lipid monolayer in the bubbles. The OMB vial is stored in a container
at a temperature between 2-8 ºC and placed on a rotating table. The OMB vial is
connected to an inlet line for suppling pure O2 gas, an O2 outlet line to avoid over
pressurizing the vial, and an OMB supply line (Figure 3.2). To avoid evaporation of the
saline in OMBs, pure O2 gas is supplied to a closed vial containing water, which supplies
humidified O2 gas to the OMBs vial.

Figure 3.2 Humidifier for OMBs
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3.2.2 Infusion
The fluid infusion system necessary to supply OMBs without exposing the
infusing fluid to the pump and surrounding atmosphere. The system delivers OMBs by a
peristaltic pump (FH100M, Thermo Fisher Scientific, Waltham, MA) shown in Figure
3.3. OMBs pass from the storage vial through tubing, connectors, valves, and swivel
before reaching the cavity. This closed loop system avoids air contamination of OMBs to
preserve their oxygen content. The system requires only a single peritoneal catheter that
is used as both an inflow and outflow line. The PLC is tunneled subcutaneously to the
back of the rat where they are fixed to a custom pedestal at least 3 days prior to the
beginning of the study. The perfusion circuit includes connecting tubing to the
infusion/scavenge ports of the PLC to the pump. The pump has a flow rate range of
0.013-760 mL/min and a maximum output of 200 rpm. This pump has an extended rotor
head for multiple tubing lines, which allows the ability to infuse multiple subjects or
multiple fluids. The adjustable cartridges allow most tubing diameters to be used for
infusing. The pump has a DB-25 input/output with 0-10 V, which allows for it to be
controlled using a LabVIEW program.

24

Figure 3.3 Peristaltic pump used for infusion

3.2.3 Pressure Measurement and Control
In order to prevent over pressurizing the cavity that could limit blood flow to the
region and can lead to abdominal compartment syndrome, IA pressure is measured and
maintained between 0 – 6 mmHg [40] [41]. For measuring the IA pressure of rats noninvasively, a pressure transducer (S7d, Gaeltec Devices Ltd, Isle of Skye, UK) is inserted
into a catheter for continuously reading pressure throughout the length of the study. The
sensor (6 French) is inserted into the inflow/outflow line at a negligible height over the
catheter port to avoid inaccuracy in the IA pressure reading.
The S7d is powered by a low voltage mains adaptor 9V DC with sensitivity of
5μV/V/mmHg. For completely accurate pressure measurements, the transducer is
compared to a calibrated pressure sensor. The transducer is connected to an amplifier
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(S7d pressure transducer amplifier, Gaeltec Devices Ltd), which has an LCD display and
is connected to a 4 channel box (Figure 3.4). Also, it has an analog voltage output port
that can be connected to a data acquisition system.

Figure 3.4 Pressure measurement and display

Pressure is regulated through the use of a fluidic control solenoid valve controlled
by LabVIEW. In case IA pressure exceeds 6 mmHg, the outflow solenoid valve opens
and a scavenge phase is initiated so that OMBs are extracted from the IP cavity until the
IA pressure goes back to the safe range.
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3.2.4 Temperature Measurement and Control
OMBs are stored at low temperatures to preserve their structure and stability for
approximately 7-10 days. Before infusing OMBs in bolus volumes to the rat’s IP cavity,
they need to be warmed close to body temperature to avoid inducing hypothermia. The
fluid warmer (i-Warm, Midmark, Kettering, OH) is a dry-heat device designed for
warming I.V. fluids safely through the heating plate (Figure 3.5). Measurements of the
temperature of the OMBs both in their storage and after passing through the fluid warmer
are needed to verify they are within the required ranges. To measure the temperatures, a
K-type thermocouples are used. One sensor is placed in a T connector at the fluid warmer
exit line. Another sensor is placed in the OMB storage to verify the temperature is
between 2-8 ºC. The thermocouple output is amplified with an AD595-AQ amp (BurrBrown, Digikey, Thief River Falls, MN). The output of the amplifier is 10 °C/mV. The
project circuit board (PCB) is designed on Altium to connect the electronics (Appendix
B). The circuit includes two K-type thermocouples, two amplifiers, +5 V power supply,
ground, and two voltage outputs. The PCB is then fabricated by the UNL Engineering
Electronics Shop (Figure 3.6).
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Figure 3.5 Fluid warmer

Figure 3.6 PCB for temperature measurement
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3.2.5 Tubing restraint
In order to prevent tubing from restraining the rat or being damaged by the rat, a
spring restraint is originally designed with a spring retractor and a counter balance
weight. Preliminary trials of the first prototype revealed that this tubing restraint did not
work properly. One rat managed to reach the tubing and pull on his catheter. Therefore, a
new design for a rat tether is under development.
The tubing will be tethered to the infusion pump via a custom swing arm that
keeps the tubing suspended above the rat and prevents entanglement (Figure 3.7). Once
in the cage, the animal will have free access to food and water.
Tethered systems require an in-dwelling catheter, a harness, and swivel. Tethered
infusion is a commonly employed technique in laboratory animals, especially rats. This is
the only option for long-term continuous access in rats [42]. The rat harness serve to
protect the catheter port and with minimal stress, a means of restraining the animal.
In addition, a counterbalance serves to reduce the weight load that the animal
experiences from the tether and swivel. An important component between the rat and the
pump is the swivel, which serves as a rotary fluid seal. Without the swivel, the animal
would be significantly encumbered in its movement, and the fluid line would occlude
partially or totally.
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Figure 3.7 Rat tether [42]

3.2.6 Data Acquisition
To connect the peristaltic pump to the DAQ (USB-6003, National Instruments,
Austin, TX), a DB-25 break out board (Winford Engineering, Auburn, MI) is required.
Figure 3.8 shows the electronics box that includes 4 solid state relays, a breakout board,
DAQ, and temperature PCB. The acrylic box design using SolidWorks is shown in
Appendix C.
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Figure 3.8 Electronics box

3.2.7 LabVIEW Control
The delivery device includes a LabVIEW interface shown in Figure 3.9 to control
several key parameters such as rat’s mass, pump speed, and type of infusate, which is
either saline or OMBs. In addition, the program provides manual override that allows the
user to control the pump and the four solenoid valves or stop the system completely. The
control program automatically calculates the bolus volume (BV) based on the rat’s mass
(M) as: BV (mL) = M (g) /10

31

Figure 3.9 LabVIEW control user interface

3.2.8 Testing the System
For preliminary trials to test the continuous system, male Wistar rats (n = 2, m ~
500 g) were successfully administered aerosolized (Lipopolysaccharide) LPS endotoxin
to induce ARDS. One rat was continuously infused OMBs at 0.5 mL/min for 12 hours
and the other for 24 hours. Another trial was conducted on a rat for 4 days for testing the
automatic infusion and scavenging system. Benchtop tests were conducted on the final
design of the automatic bolus system.

3.3 Results and Analysis
In ARDS rats, SpO2 decreased steadily following administration of endotoxin in
untreated controls while SpO2 increased after 24 hours for ARDS rats treated with OMBs
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(Figure 3.10). The device lacked automatic scavenging with a waste flow line. Instead,
excess OMBs were removed by manually drawing them out from the cavity with a
syringe connected to the PLC every 2 hours.
One preliminary trial on a rat was conducted with the automatic continuous
infusion and scavenging system and it revealed that there was advanced tissue obstruction
and growth in the PLC after four days. This may be caused by the constant suction
applied to the outflow line leading to suction of tissue inside the pores of the lavage
catheter.
Benchtop testing of the final design of the bolus delivery system has been
successfully completed. The tubing restraint was not working properly. The new design
of the rat tether is still under development. The bolus delivery system will be tested on
rats to ensure that infusion and scavenging can be maintained for two weeks. Once
testing is successful, we will proceed with validation trials with saline, inert gas
microbubbles, and OMBs.
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Figure 3.10 Oxygen saturation taken by pulse oximetry [43]
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Chapter 4: Diffusion Modeling
4.1 Introduction
A previous theoretical and experimental study was undertaken by Borden et al. to
determine the fate of a microbubble suddenly suspended in a multi-gas environment, such
as the bloodstream [33]. They developed a numerical model based on the classic Epstein
and Plesset theory that predicts the rate of microbubble dissolution in a single gas
medium. Experimental verification of the model was performed with individual sulfur
hexafluoride (SF6) microbubbles coated with a soluble surfactant. Microbubbles placed in
a perfusion chamber containing N2 and O2 in an aqueous medium initially grew due to
the influx of nitrogen and oxygen and then dissolved under surface tension.
In contrast, our study involves infusion of oxygen filled microbubbles into the
intraperitoneal cavity of rats with ARDS. This is a new method being explored that
requires more studies in theory and in vivo. A lack of literature on modeling oxygen
delivery from OMBs to peritoneum tissue prompted a need for this study. In addition,
there is not enough data that support one method of infusion in delivering oxygen (bolus
vs. continuous circulation). A model for diffusion would predict how fast oxygen diffuses
across the multiple layers of tissue in the surrounding abdomen. Depending on how fast
diffusion reaches steady state, this would determine the maximum dwell duration of
OMBs. A simple 1D mathematical model was developed using Fick’s laws to determine
the oxygen transport rate and how it compares to the normal oxygen consumption need.
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4.2 Materials and Methods
For OMBs injected into the IP cavity of rats, the pathway of gas exchange across
the PM is assumed to be homogeneous and has one spatial dimension for simplification.
OMBs are assumed to have a constant O2 concentration when injected in the IP cavity
and no oxygen is consumed by surrounding tissue. The gas components are assumed to
behave ideally and no convection occurs.
Oxygen molecules move down their concentration gradient diffusing out of
OMBs to reach RBCs in the PM blood capillaries (Figure 4.1). To reach the capillaries in
the peritoneum, oxygen must first dissolve in the saline of the OMBs and then diffuse
through the mesothelium, cells and interstitial tissue. To reach the capillaries in the
parenchymal tissue beneath the PM, oxygen must first dissolve in the saline of the OMBs
and then diffuse through the PM layers and muscle tissue (Figure 4.2). The rate of
diffusion depends on the surface area of the PM and the flux density. Increasing the area
or the concentration gradient leads to faster diffusion. The diffusion rate using Fick’s first
law is written as
dC

J = −AD ( dx )

x=L

= −AD

C0 −Cs

(1)

L

where the diffusion zone is equal to the thickness (L) of the tissue between the OMBs and
blood capillary wall, C0 and Cs are the dissolved O2 concentrations in blood capillaries
and in the peritoneal cavity, respectively, D is the diffusivity, and A is the surface area of
the PM, which can be calculated using the rat’s mass (M) [44]
𝐴(𝑖𝑛 𝑐𝑚2 ) = 1.61𝑀(𝑖𝑛 𝑔) + 40.5

(2)
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The dissolved gas concentration at equilibrium depends on both partial pressure
(P) and solubility (α) according to Henry’s law
𝐶 = α𝑃

(3)

The parameters of solubility and diffusivity for O2 in plasma and tissue are 0.003
(mL/dL)/mmHg and 1.7 x10-5 cm2/s, respectively [45]. The PM has a reported thickness
of approximately 90 µm in rats [46]. However, because rats have relatively few blood
vessels in the peritoneum, most oxygen transport could end in parenchymal tissue blood
vessels, which are below the PM at a thickness between 0.5 – 1 mm [47]. Both cases are
examined in the calculation of the diffusion rate. If diffusion occurs over the PM by
itself, O2 will be absorbed by blood capillaries at peritoneum thickness of 90 µm (case 1).
In contrast, if diffusion reaches the visceral organ capillaries, then the average tissue
thickness is 0.75 mm (case 2). We used Fick’s second law [48] that predicts how
diffusion causes the concentration (Cx) to change with time. The solution to Fick’s
second law [48] is
𝐶𝑥 −𝐶0
𝐶𝑠 −𝐶0

𝑥

= 1 − 𝑒𝑟𝑓 (2√(𝐷𝑡))

(4)

where x is the thickness of tissue and t is time.
MATLAB was used to solve and plot Cx (Appendix D). In addition, the oxygen
supply from OMBs was compared to the oxygen metabolism in resting rats, which is ~12
mL/min/kg [49].
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Figure 4.1 Simplified model of oxygen diffusion from OMBs to the layers of the
peritoneum
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Figure 4.2 Simplified model of oxygen diffusion from OMBs to the layers of
parenchymal tissue

4.3 Results and Analysis
A simplified model for diffusion of oxygen from OMBs to the peritoneum blood
was constructed. The mass of rats used in the mathematical model was 538 g, equal to the
average mass of rats used in the in vivo experiments. Using equation 2, the peritoneal
surface area was calculated to be 907 cm2. The oxygen partial pressure (PO2) in the
peritoneal blood capillaries is normally 40 mmHg [50]. The average rat IP pressure
measured after a single bolus injection of OMBs was ~2 mmHg above atmospheric
pressure, so PO2 in OMBs was 762 mmHg. Thus, the pressure gradient of OMBs-to-blood
was 722 mmHg.
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The oxygen content inside OMBs is 70 mL/dL, while O2 bound to hemoglobin in
RBCs has a concentration of 15 mL/dL within venous blood. However, the diffusion rate
is driven by the dissolved oxygen concentration gradient. Using equation 3, the
concentration of dissolved O2 in venous blood is C0, which is equal to 0.12 mL/dL, while
the concentration of dissolved O2 in OMB saline is Cs, which is equal to 2.29 mL/dL. The
OMBs-to-blood dissolved O2 concentration gradient is their difference of 2.17 mL/dL.
An algorithm was developed using MATLAB to solve and plot the oxygen
diffusion kinetics. If the diffusion thickness is 90 µm, then the oxygen diffusion rate
would be 0.038 mL/s, and this supplies 34.4% of the total oxygen consumption needed in
rats. However, if the thickness is 0.75 mm, then the diffusion rate would be 0.0045 mL/s
supplying only 4.2% of the total oxygen consumption of rats. Tissue at depth of 90 µm
(Figure 4.3a) will reach O2 concentration of 1.94 mL/dL within 1 minute. Steady state is
reached after 35 seconds. Tissue at depth of 0.75 mm (Figure 4.3b), will reach O2
concentration of 1.77 mL/dL within 30 minutes. Steady state is reached after 41.7
minutes.
These results show that in theory oxygen delivered by OMBs in vivo occurs at a
range between 0.0045 and 0.038 mL/s. Since oxygen delivery requires time (up to 42
min) to reach steady state, a bolus dosage administered periodically to IP cavity would be
more efficient and cost effective than continuous infusion of OMBs. A 60 mL bolus
would require a maximum dwell time of approximately 42 min to reach steady state in
diffusion, but further in vivo tests are required to validate this dwell time.
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Figure 4.3 Mathematical model of 1D diffusion of oxygen from OMBs to peritoneal
blood over time
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Chapter 5: In vivo Study
5.1 Introduction
In chapter 4, we have developed a simple model that predicts oxygen delivery
from OMBs injected intraperitoneally. In theory the oxygen diffusion rate was found to
be between 0.0045and 0.038 mL/s. This range for diffusion rate is relatively wide due to
several modeling limitations including 1D pathway and no oxygen consumption by tissue
considerations. To validate our model and to obtain a more precise oxygen transport rate,
an in vivo experiment was designed. A previous study by Kheir et al. [35] showed that
OMBs when mixed with deoxygenated blood ex vivo deliver O2 in 4 sec. The purpose of
this experiment is to study not only oxygen delivery by OMBs, but also possible CO2
absorption and other gas(s) from surrounding tissue in vivo. To validate gas diffusion
properties of OMBs in vivo, the gas content of OMBs was measured by a gas analyzer
before and after injection to the rat’s IP cavity. Fresh OMBs ideally contain pure oxygen
gas if handled carefully avoiding air contamination. Measured gas concentrations were
further converted to volumes and diffusion rate and depth were calculated. The
experimental results for diffusion were then compared to the modeled theoretical values.

5.2 Materials and Methods
Male Wistar rats (n = 4, 538 ± 48 g) were housed and acclimated for four days,
and cared for according to the University of Nebraska-Lincoln IACUC guidelines. All
rats were sedated using ketamine-xylazine (18-2 mg/kg) and placed in the supine position
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on a warming pad (T/pump Classic, Gaymar, Orchard Park, NY) set at 38 °C to maintain
body temperature (Figure 5.1a). Pulse oximetry (PhysioSuite, Kent Scientific Corp.,
Torrington, CT) measurements were taken throughout the whole experiment to measure
the heart rate (HR) and oxy-hemoglobin saturation (SpO2). The pulse oximeter clip was
placed on the rat’s hind leg and data was recorded every second until the experiment was
terminated. After the rat was fully sedated and unresponsive to pain delivered by paw
pinches, a small incision into the skin was made to expose the fascia of the abdominal
wall. An inflow tube (3.2 mm, Tygon) and outflow catheter (JP7, Mila International Inc,
Erlanger, KY) were surgically implanted in the IP cavity and sutured closed (Figure
5.2b). A valve was placed on the exterior end of the outflow catheter to vacuum the line
with a syringe. A pressure sensor (S7d, Gaeltec Devices Ltd., Isle of Skye, UK) and the
injection syringe were connected to the inflow line. IP pressure was monitored and
maintained below 6 mmHg to avoid disruption of hemodynamics in the rat’s abdomen
[51] [ 40]. The gas content of a 10 mL OMB sample collected directly from the OMB vial
was analyzed before injection (t = 0). A single 60 mL OMB bolus, a safe volume for
intraperitoneal injection of fluid in rats [38], was infused within 1 minute into the IP
cavity using the inflow line. Immediately after, the IP pressure was recorded.
Subsequently, 10 mL OMB samples were collected from the IP cavity every 5 minutes.
Samples were manually crushed in the syringe by applying pressure to the plunger and
then placed on a heating pad (70 °C) for 10 minutes (Figure 5.1b). This technique broke
the lipid monolayer of the OMBs and released the gas content of the sample into the
headspace (Figure 5.2c). The gas headspace was carefully transferred to another syringe
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to be analyzed by an O2 and CO2 headspace gas analyzer (Gaspace 6600, Illinois
Instruments, Inc., Johnsburg, IL). The syringe containing the gas sample was introduced
into the gas analyzer by auto-injection (Figure 5.1c and Figure 5.2d). The entire process
avoided air contamination to get the most reliable reading. Finally, after 20 minutes and 4
OMB samples were collected rats were euthanized by CO2 inhalation.
One way valves were a source of inevitable air contamination added to each
sample. The total volume of contamination, Vair, was found to be approximately 0.85 mL
and composed of atmospheric air. A species balance was used to find the adjusted sample
concentrations (xsample) for O2, CO2 and N2 neglecting water vapor and other trace gases.
The overall volume balance was found with the following equations.

𝑥𝑂2,𝑠𝑎𝑚𝑝𝑙𝑒 = 𝑥𝑂2,𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 (𝑉

𝑉𝑎𝑖𝑟

𝑠𝑎𝑚𝑝𝑙𝑒

+ 1) − 0.21 (𝑉

𝑉𝑎𝑖𝑟

𝑠𝑎𝑚𝑝𝑙𝑒

𝑥𝑁2,𝑠𝑎𝑚𝑝𝑙𝑒 = (1 − 𝑥𝑂2,𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 − 𝑥𝐶𝑂2,𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 ) (𝑉

𝑉𝑎𝑖𝑟

𝑠𝑎𝑚𝑝𝑙𝑒

𝑥𝐶𝑂2,𝑠𝑎𝑚𝑝𝑙𝑒 = 𝑥𝐶𝑂2,𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 (𝑉

𝑉𝑎𝑖𝑟

𝑠𝑎𝑚𝑝𝑙𝑒

)

(5)

+ 1) − 0.79 (𝑉

𝑉𝑎𝑖𝑟

𝑠𝑎𝑚𝑝𝑙𝑒

) (6)

+ 1)

(7)

5.3 Statistical Analysis
A linear mixed model with repeated measures with AR(1) covariance structure
followed by a t-test were performed on the estimated slopes and intercepts of recorded
SpO2 data before injection and after injection of OMBs. A p-value threshold of 0.05 was
considered statistically significant.
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Figure 5.1 Experimental setup for headspace gas analysis of OMBs

Figure 5.2 Pictures taken during experiment (a) OMB extraction (b) implanted catheters
(c) crushed OMBs (d) headspace gas analysis
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5.4 Results and Analysis
Intraperitoneal pressure was recorded after OMB bolus injection. The average
measurement was 1.93 ± 0.5 mmHg (n = 4). Before injection of OMBs at time 0 (Figure
5.3), the rats’ average SpO2 was approximately 83.8 ± 0.8%, while the average HR was
231.0 ± 10.3 bpm. After OMB bolus injection and 20 minutes dwell time, SpO2 increased
to 86.2 ± 2.2%, while HR decreased to 226.2 ± 9.0 bpm. The fitted linear regression
model for SpO2 data showed that the slope of the line before injection was – 0.0043
indicating that there was no change in SpO2 and had no statistically significant increase
with time (p > 0.05). After injection of OMBs, there was a slight increase of SpO2 after
dwell with a slope of +0.057, which was found to be statistically significant (p < 0.05)
using the same model and statistical test.
After crushing the OMBs, the gas volume was recorded for each sample (Figure
5.4a). Fresh OMBs had 67% gas volume fraction. This fraction decreased to 34.6 ± 8.2%
after 20 minutes of dwell time. The measured gas contents were adjusted for
contamination using equations 5, 6 and 7. Figure 5.4b shows the adjusted gas content
detected in OMBs before and after dwelling in the IP cavity. Fresh OMBs had an average
of 93.8 ± 3.9%, 0% and 6.2 ± 3.9% for O2, CO2 and N2, respectively. After 20 minutes
of dwell time, OMBs had an average of 76.3 ± 7.7%, 5.5 ± 1.2% and 17.2 ± 7.6% for O2,
CO2 and N2, respectively.
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Figure 5.3 Pulse oximeter measurements (LS-mean) include (a) heart rate (beats per
minute) and (b) oxy-hemoglobin saturation (%) before and after OMB bolus injection to
the rat’s IP cavity (n = 4)
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Figure 5.4 (a) Gas vol% composition (average ± SD) of OMBs and (b) gas content of
OMBs after OMB infusion to the cavity (n = 4)
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Gas percentages obtained by the gas analyzer were further analyzed to determine
the volume of O2 that diffused from OMBs to the rat’s body. The calculated diffusion
volumes of O2, CO2 and N2 across the PM over 20 min are shown in Table 5.1. Negative
values represent diffusion in the opposite direction, from the rat’s body into the OMBs.
OMBs in the IP cavity had a total of 16.5 mL O2 diffused over 20 minutes. This was
equivalent to a diffusion rate of 0.014 mL/s. OMBs still carried 57.6 % of their initial O2
volume after 20 min of dwell. Using the obtained diffusion rate, the diffusion depth was
calculated to be 236 µm, and the oxygen supply was 13.1% of the total need. These
values were within the range of our calculated theoretical diffusion model shown in Table
5.2.
These results indicate that after 20 minute dwell duration, OMBs (60 mL) still
carry more than half of their initial oxygen content. In theory, a 45 min dwell would be
enough time for oxygen to diffuse. These results confirm our bolus volume and dwell
time predicted by our model in chapter 4. Therefore, for ~ 500 g rats a bolus volume of
60 mL OMBs will be allowed to dwell for ~ 45 minutes in the IP cavity of rats.
Additional trials are needed to test this dwell duration on hypoxic rats.
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Table 5.1 Diffused volume (average ± SD) of gases in mL between OMBs and
surrounding tissue during dwell in IP space (n = 4)
Time
(min)

VOMBs in IP

VO2 diffused

VCO2
diffused

VN2 diffused

0

60

--

--

--

5

60

9.8 ± 4.4

-0.4 ± 0.1

-5.2 ± 2.2

5+

50

--

--

--

10

50

-1.4 ± 5.5

-0.2 ± 0.2

2.3 ± 2.9

10+

40

--

--

--

15

40

4.4 ± 1.8

-0.2 ± 0.2

0.3 ± 0.9

15+

30

--

--

--

20

30

3.6 ± 1.8

-0.3 ± 0.2

0.3 ± 0.4

50
Table 5.2 Modeled versus experimental diffusion rate (J), diffusion depth (L) and oxygen
supply
Model

Experiment

Case 1

Case 2

Depth (µm)

90

750

236

Rate (mL/s)

0.038

0.0045

0.014

% O2 supply

34.4

4.2

13.1
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Chapter 6: Discussion and Conclusions
Our first experiment determined a reliable and efficient method to extract the
OMBs from the intraperitoneal space. A peritoneal lavage catheter (JP7, Mila
International) can be used for long term studies involving OMB treatment of rats with
mild to severe ARDS. This catheter can be surgically implanted in the IP space and used
for both infusion and scavenging of OMBs due to its flexibility, wide diameter, numerous
pores, and increased length. In addition, this catheter can be used in experiments that
requires extraction of OMBs from the IP space to test for CO2 absorption and O2 delivery
by OMBs.
Testing the effect of PMO as a potential therapy for ARDS requires at least 3 days
of treatment. Thus, rats need to be conscious and able to move freely around their cage
during this study. We have designed and developed an infusion system that automatically
and intermittently infuses bolus dosage of OMBs to a rat’s IP cavity. The system will be
used for studying PMO with conscious rats of mild to severe ARDS. We have completed
a pilot study (n = 2) to verify the benefits of PMO therapy utilizing a continuous infusion
device. There appears to be short-term improvement in reduction of hypoxia using pulse
oximeter measurements of SpO2. However, the preliminary trial revealed advanced tissue
obstruction and growth in the catheter after four days. This was a major problem as it
prevented further removal of fluid from the cavity. Therefore, the design was revised to
implement a periodic bolus system that is simpler and effective. This would allow OMBs
to dwell in the cavity for gas exchange to occur between OMBs and peritoneum blood.
Benchtop testing of the final design of the bolus delivery system has been successfully
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completed. Since the tubing restraint was not working properly, a new design of a rat
tether will be developed and tested shortly. In future trials, rats will be infused with either
a bolus of sterile oxygenated saline, inert gas microbubbles (IMBs) as controls or OMBs
for PMO therapy with four rats from each group. Upon completion of the device, we will
evaluate the effect of PMO therapy on survival, lung health, and oxygen saturation.
The significance of this study was to give a better understanding of how oxygen
microbubbles exchange gas with peritoneal tissue when infused to the IP cavity. A model
for diffusion predicted how fast oxygen will diffuse across the multiple layers of tissue in
the surrounding abdomen and how that relate to the normal oxygen consumption need. In
theory oxygen delivered by OMBs in vivo occurs at a range between 0.0045 and 0.038
mL/s. This would supply between 4.2% and 34.4% of the total oxygen consumption
needed in resting healthy rats.
There are several limitations to this mathematical model. The O2 consumption by
tissue in surrounding abdominal wall and internal organs was not accounted for. Oxygen
consumption by tissue would decrease the amount of oxygen absorbed by blood
capillaries. Also, it was assumed that OMBs maintain pure oxygen concentration, which
was not the case in vivo because other gases diffuse into the bubbles as shown in the
headspace gas measurements. The mathematical model was based on time and one
dimensional space because of the complicated model schemes required for the true
dynamics of diffusion in the 3D abdomen.
The diffusion profile obtained from the in vivo study was compared to the
modeled diffusion profile. The calculated diffusion zone (236 µm) was larger than the
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thickness of the PM (90 µm), but less than the parenchymal tissue thickness (750 µm).
This indicates that oxygen diffused past the PM to reach underlying tissue in the
abdominal wall and internal organs, however oxygen did not diffuse to the entire depth of
parenchymal tissue in rats (0.5-1 mm thick). In addition, the oxygen supplied by the
OMBs (0.014 mL/s) was lower than the normal oxygen consumption of rats as expected
because the study was conducted on healthy rats. In addition to having catheter problems
using the continuous infusion system, these results changed our initial device design from
continuous circulation of OMBs to bolus periodic delivery. A 60 mL OMB bolus would
require a dwell time of approximately 45 min to reach steady state in gas exchange, but
further in vivo tests are required to validate this dwell duration on ARDS rats.
Pulse oximeter data indicated that bolus injection of OMBs did not cause any
harm to the animal’s condition. General anesthesia causes low oxygen saturation and HR
measured by peripheral pulse oximetry [52]. After 20 min, there was a slight increase in
SpO2 by ~2.5%. This increase was statistically significant though it may not be clinically
relevant. These results indicate that peritoneal membrane oxygenation was not harmful
and may be potentially effective in delivering oxygen to hypoxic rats.
The greater decrease in oxygen content (Figure 5.4b) measured at 5 min
compared to the 10 min sample could be due to air contamination. The outflow line was
manually vacuumed directly after implantation into the IP cavity. Since this is not a
perfect vacuum and it is unlikely that oxygen was reentering the OMBs, residual air
within the line may explain why the sample taken at 10 min had more % O2 than the 5
min sample. Another contributing factor could be that the gas volumes of the samples

54
was different. Fresh OMBs are composed of 70% O2, 30% saline, and <1% lipids. After
OMBs dwell in the IP cavity, gas diffuses from OMBs to the body and vice versa thus
changing the ratio of gas to saline volume. More oxygen diffused from OMBs than other
gases being absorbed by the bubbles, so the gas percentage decreased gradually with
time.
One of the gases detected in OMBs was CO2, which cannot be due to air
contamination because room air has only 0.003% CO2 [53]. This gives evidence that
OMBs can uptake CO2 from the body. Healthy rats have a low blood concentration of
CO2, which explains the low amount of CO2 detected in OMBs after dwelling in the IP
cavity. Other traces of gases are unknown but assumed to be N2 because the nitrogen
partial pressure in venous blood is 573 mmHg [54]. Venous PN2 is much greater than
venous PCO2, PO2, and PH2O which are 46, 40, and 47 mmHg, respectively. Fresh OMBs
have PO2 of 760 mmHg and PN2 of 0 mmHg ideally. Thus, there is a high blood-to-OMBs
nitrogen pressure gradient that leads to a flux of N2 from surrounding venous tissue to
OMBs dwelling in the IP space. This may be of great potential benefit for removal of
excess nitrogen gas in decompression sickness, a common condition that affects divers
[55]. Further testing will be conducted to validate the other gas(s) absorbed by OMBs.
In conclusion, we developed a preliminary mathematical model that portrays the
kinetics of oxygen transfer between OMBs and the body. In vivo results show that
oxygen was delivered from OMBs by diffusive transport through the peritoneum into the
adjacent blood and tissue of the abdominal wall and internal organs. CO2 was also able to
diffuse from the body into OMBs. Also, peritoneal oxygenation with OMBs did not
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negatively alter the physical condition of the rats. Both mathematical modeling and
animal experiments were applied on healthy rats with normal levels of oxygenation and
respiratory rate. This serves as a reference for future studies involving hypoxia. We are
able to demonstrate in vivo that OMBs not only can provide O2 to the body, but also can
absorb CO2 and possibly other gases, such as N2, from the body. This is very significant
as it provides an alternative extrapulmonary technique of ventilation that can have
significant implications in the future.
Our future goals involve improving our model using advanced numerical methods
or finite elements analysis (FEA) that would be more accurate in simulating diffusion of
multiple gases [56]. The transport of O2, CO2, and N2 will also be modeled in hypoxic
conditions. During hypoxemia, a lower oxygen concentration in blood increases the
OMBs-to-blood oxygen concentration gradient thus increases the oxygen diffusion rate.
In contrast, CO2 accumulation in blood and tissue during hypoxia will drive CO2
diffusion in the opposite direction thus OMBs will absorb a higher amount of CO2.
Future work will include in vivo experiments on a hypoxic rat model of acute
respiratory distress syndrome where we predict faster transport of oxygen and a more
significant removal of carbon dioxide from the body due to the respiratory system being
compromised. The oxygen delivery rate will be evaluated in supplying enough oxygen to
accommodate the compromised lungs. In addition, arterial blood gases will be taken
before and after infusion of OMBs to rat’s IP cavity and tested for clinically significant
increase in PaO2.
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We will further study the potential side effects of infusing OMBs to the
intraperitoneal space by conducting autopsy and toxicology tests of abdominal organs. In
addition, one way to determine the fate of OMBs in vivo would be to radioactively label
the lipids to test their absorption or breakdown. In addition, radioactive labeling O2 gas
would be another way to detect the pathway of oxygen delivered by OMBs.
The Berlin criteria used for classifying ARDS may also be used as a selection
criteria for patients requiring peritoneal membrane oxygenation. PaO2/FiO2 is an
important determinant of low levels of oxygen in blood. Further literature review and
research need to be conducted to find a suitable selection criteria for ARDS patients
requiring PMO.
Patients with mild-to-moderate ARDS can be potentially treated with PMO either
in tandem with current ventilation practices such as mechanical ventilation or by itself.
Infusion of OMBs intraperitoneally would provide supplemental oxygenation to
surrounding tissue in the abdomen and blood. Pulmonary ventilation supported by MV
and supplemental extrapulmonary ventilation provided by PMO would supply enough
oxygen that will hopefully prevent these patients to reach end stage ARDS. This would
decrease the chance of these patients requiring ECMO, which has a high mortality rate.
We foresee the implementation of peritoneal membrane oxygenation as a treatment and
first response aid for respiratory distress in intensive care units and combat field settings
in the future.
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Appendix A: Aspirated OMB Volumes
Table A.1 Recorded volumes of aspirated OMBs from IP space in rats (n = 5)
Volume of aspirated OMBs (mL)
Rats

18G

16G

14G

11G

10G

SOTT

PLC

1

0

0

0

1

0

1

30

2

4

19

8

18

11

16

37

3

0

23

1

0

6

11

33

4

1

0

0

43

0

3

20

5

4

35

0

0

0

7

30

Mean ± SD 1.8 ± 2.1 15.4 ± 15.2 1.8 ± 3.5 12.4 ± 18.7 3.4 ± 4.5 7.6 ± 6.1 30 ± 6.3
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Appendix B: Temperature Circuit Design

Figure B.1 Temperature circuit board design using Altium

66

Appendix C: SolidWorks Drawings

Figure C.1 Lower face dimensions of electronics box
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Figure C.2 Top face dimensions of electronics box

Figure C.3 Side face dimensions of electronic box
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Appendix D: Modeling Program
Matlab code for predicting the concentration change with time of peritoneum tissue after
injection of OMBs.
s = input('Please select case(1)/(2): ');
if s == 1
x=0:.1:90;% thickness of PM (um)
y=0:.1:60; %time (seconds)
else
x=0:1:750;% thickness of parenchymal tissue(um)
y=0:1:1800;
end
D = 1.7*10^3; %Diffusion coefficient of oxygen in tissue
(um2/s)
C0=0.12; % concentration of oxygen in plasma (ml/dl)
Cs=2.286; % concentration of oxygen in peritoneal cavity
filled with OMBs(ml/dl)
figure(2); hold on
n = length(x);
for i = 150:150:n
X = x(i);
K = ((C0-Cs)* erf(X./(2*sqrt(D.*y)))+Cs); %Solution to
Fick's second law where K is concentartion (ml/dl)
plot(y,K,'LineWidth',3);
end
xlabel('Time (seconds)','Fontsize',24)
ylabel('O2 Concentration (mL/dL)','Fontsize',24)

